BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 – November 20, 2026.
In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium’s antibody-drug conjugates session.
Oral Presentation Details:
Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Faye M. Johnson, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Session: Proffered Papers: Clinical Trials
Abstract number: 3LBA
Date and time: Thursday, November 19, 2026, from 10:00 a.m. – 11:30 a.m. CET
Location: Room 111 + 112
Poster Presentation Details:
Poster Title: In vitro characterization of the mechanism of action of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin
Session Title: Antibody-drug conjugates
Session Day: Wednesday, November 18, 2026, from 12:00 p.m. – 7:00 p.m. CET
Location: Exhibition Hall
Poster Board Number: PB-054
Poster Title: Micvotabart pelidotin in combination with EGFR-targeted therapy improves duration of response in HNSCC PDX models
Session Title: Antibody-drug conjugates
Session Day: Wednesday, November 18, 2026, from 12:00 p.m. – 7:00 p.m. CET
Location: Exhibition Hall
Poster Board Number: PB-079
About Micvotabart Pelidotin (MICVO)
Micvotabart pelidotin (MICVO, formerly PYX-201) is an antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.
MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Pyxis Oncology Contact
IR@pyxisoncology.com
Media gallery
